Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients (NCT04337255) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
United States250 participantsStarted 2021-12-14
Plain-language summary
To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular disease in a Phase Ill randomized controlled trial of 250 patients hospitalized for acute ischemic stroke, aged 55 years or older, and without dementia who are discharged home following hospitalization.
Who can participate
Age range55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
* Inclusion Criteria
* Men and women, 55 years of age - inclusive- or older
* Acute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan
* Written informed consent by patient prior to study participation
* Willingness to complete all assessments and participate in follow-up
* Willing to participate and give informed consent
* Adequate Visual and auditory acuity to undergo neuropsychological testing
* Exclusion criteria
* CDR\>=0.5
* Nuts, berries, olive oil, or fish allergies
* Use of medications to treat Alzheimer's disease or Parkinson's disease
* Aphasia
* Conditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years
* Report of alcohol or substance abuse within six months, or heavy alcohol consumption (\>2 drinks/d women; \>3 drinks/d men)
* Unstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV)
* Cancer treatment \<= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion)
* Illness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel re…